Comparison of capillary blood self-collection using the Tasso-SST device with venous phlebotomy for anti-SARS-CoV-2 antibody measurement

King, Elise; Garrett, Haley E.; Abernathy, Haley; Cassidy, Caitlin A.; Cabell, Cameron R.; Shook-Sa, Bonnie; Juliano, Jonathan J.; Boyce, Ross M.; Aiello, Allison E.; Ciccone, Emily J.

doi:10.1016/j.jim.2023.113523

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our experience, the failure rate for collecting a minimum of 100 μl of blood was less than 5%. Other studies using the Tasso-SST device reported failure rates (either insufficient blood or inability to collect any blood) ranging from 3.3% to 20% [ 4 , 8 , 9 , 27 , 28 ]. To achieve the desired blood volume, we recommend providing a sufficient number of devices, calculated by assuming no more than a median blood volume of 450 μl per device, with extra devices to accommodate suboptimal volume (250 uL (lower volume quartile) and device failure (5%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility, acceptability, and safety of a novel device for self-collecting capillary blood samples in clinical trials in the context of the pandemic and beyond

Dasari,

Smyrnova,

Leng

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background Home blood self-collection devices can enable remote monitoring, but their implementation requires validation. Our objectives were to explore (i) the impact of sampling sites and topical analgesia on capillary blood volume and pain perception and (ii) the safety, acceptability, and failure of capillary self-collection among adults and children using the Tasso-SST device. Methods We conducted a two-phase study. The investigational phase consisted of two on-site cross-sectional studies in healthy adult participants (≥ 12 years) and children (1–17 years) with their accompanying parent. Adults received 4 capillary samplings, where puncture sites and topical analgesia were randomized in a factorial design, and a venipuncture; children (and one parent) had one capillary sampling. The two co-primary outcomes were blood volume and pain. The implementation phase was conducted in two multicentre trials in participants choosing remote visits; blood volume, collection failure, adverse events, and satisfaction were documented. Results In the investigational phase, 90 participants and 9 children with 7 parents were enrolled; 15 adults and 2 preschoolers participated in the implementation phase. In the adult investigational study, the device collected a median (25%, 75%) of 450 (250, 550) μl of blood with no significant difference between the puncture site, topical analgesia, and its interaction. Using topical analgesia reduced pain perception by 0.61 (95% CI: 0.97, 0.24; P <0.01) points on the 11-point scale; the pain reduction varied by puncture site, with the lower back showing the most significant decrease. Overall, combining all studies and phases, the median volume collected was 425 (250, 500) μl, and the device failure rate was 4.4%; minor adverse effects were reported in 8.9% of the participants, all were willing to use the device again. Conclusion Capillary blood self-collection, yielding slightly less than 500 μl, proves to be a safe and relatively painless method for adults and children, with high satisfaction and low failure rates. The puncture site and topical analgesia do not affect blood volume, but topical analgesia on the lower back could reduce pain.

show abstract

Section: Discussionmentioning

confidence: 99%

“…3.3% to 20% [4,8,9,27,28]. To achieve the desired blood volume, we recommend providing a sufficient number of devices, calculated by assuming no more than a median blood volume of 450 μl per device, with extra devices to accommodate suboptimal volume (250 uL (lower volume quartile) and device failure (5%).…”

Section: Plos Onementioning

confidence: 99%

Feasibility, acceptability, and safety of a novel device for self-collecting capillary blood samples in clinical trials in the context of the pandemic and beyond

Dasari,

Smyrnova,

Leng

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

Capillary blood self‐collection for high‐throughput proteomics

El‐Sabawi,

Huang,

Tanriverdi

et al. 2024

Proteomics

View full text Add to dashboard Cite

In this study, we sought to compare protein concentrations obtained from a high‐throughput proteomics platform (Olink) on samples collected using capillary blood self‐collection (with the Tasso+ device) versus standard venipuncture (control). Blood collection was performed on 20 volunteers, including one sample obtained via venipuncture and two via capillary blood using the Tasso+ device. Tasso+ samples were stored at 2°C–8°C for 24‐hs (Tasso‐24) or 48‐h (Tasso‐48) prior to processing to simulate shipping times from a study participant's home. Proteomics were analyzed using Olink (384 Inflammatory Panel). Tasso+ blood collection was successful in 37/40 attempts. Of 230 proteins included in our analysis, Pearson correlations (r) and mean coefficient of variation (CV) between Tasso‐24 or Tasso‐48 versus venipuncture were variable. In the Tasso‐24 analysis, 34 proteins (14.8%) had both a correlation r > 0.5 and CV < 0.20. In the Tasso‐48 analysis, 68 proteins (29.6%) had a correlation r > 0.5 and CV < 0.20. Combining the Tasso‐24 and Tasso‐48 analyses, 26 (11.3%) proteins met these thresholds. We concluded that protein concentrations from Tasso+ samples processed 24–48 h after collection demonstrated wide technical variability and variable correlation with a venipuncture gold‐standard. Use of home capillary blood self‐collection for large‐scale proteomics should be limited to select proteins with good agreement with venipuncture.

show abstract

Comparison of capillary blood self-collection using the Tasso-SST device with venous phlebotomy for anti-SARS-CoV-2 antibody measurement

Cited by 2 publications

References 15 publications

Feasibility, acceptability, and safety of a novel device for self-collecting capillary blood samples in clinical trials in the context of the pandemic and beyond

Feasibility, acceptability, and safety of a novel device for self-collecting capillary blood samples in clinical trials in the context of the pandemic and beyond

Capillary blood self‐collection for high‐throughput proteomics

Contact Info

Product

Resources

About